Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology firm dedicated to developing precision therapies for genetically defined diseases, has announced new preclinical findings regarding its pan KRAS(ON) inhibitor. This data was presented in a poster session at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, Massachusetts from October 22 to 26, 2025.
In a statement, Andrew Robbins, President and Chief Executive Officer of Cogent, expressed enthusiasm about sharing the updated results, highlighting the potential of their lead molecule to emerge as a best-in-class treatment option. Robbins stated, “We are excited today to share updated data from our pan KRAS(ON) program which demonstrates a potential best-in-class profile for our lead molecule.”
Cogent aims to progress this program further, with plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in 2026. This step marks a significant milestone in their ongoing efforts to address cancer therapies targeting KRAS mutations, which are prevalent in various types of cancer.
The conference serves as a platform for leading researchers and companies in the field to present advancements in cancer treatment, and Cogent”s presentation is part of its commitment to advancing innovative therapies that can improve patient outcomes in oncology.
